1999
DOI: 10.1089/107999099313631
|View full text |Cite
|
Sign up to set email alerts
|

Detection and Characterization of Antibodies to PEG-IFN-alpha2b Using Surface Plasmon Resonance

Abstract: Some patients treated with type I interferon (IFN) preparations develop neutralizing antibodies that may abrogate any clinical benefit. We have a new complex of polyethylene glycol12000 and IFN-alpha2b (PEG-IFN-alpha2b) in clinical trials and need to be able to detect any antibodies formed specifically against the complex. We have, therefore, devised a method based on measurement of surface plasmon resonance (SPR) in the BIACORE 2000 apparatus. PEG-IFN-alpha2b is anchored to one flow cell on the sensor chip, I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2000
2000
2011
2011

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(8 citation statements)
references
References 16 publications
0
8
0
Order By: Relevance
“…Recent work has shown that macromolecules such as poly(ethylene glycol) can be used to improve significantly the bioavailability and pharmacokinetics of known drugs 90, 91. A clear example, already a rousing commercial success, is Schering‐Plough's PEG Intron, in which a short strand of monomethoxy poly(ethylene glycol) [PEG; molecular weight = 12,000 Da] is attached to interferon α‐2b, a water‐soluble protein (molecular weight = 19,271 Da) produced by recombinant DNA techniques 92. The polymer–drug conjugate is much more effective that the parent interferon alone in the treatment of hepatitis C.…”
Section: Nanomedicine: Dendrimers In Macromolecular Therapeuticsmentioning
confidence: 99%
“…Recent work has shown that macromolecules such as poly(ethylene glycol) can be used to improve significantly the bioavailability and pharmacokinetics of known drugs 90, 91. A clear example, already a rousing commercial success, is Schering‐Plough's PEG Intron, in which a short strand of monomethoxy poly(ethylene glycol) [PEG; molecular weight = 12,000 Da] is attached to interferon α‐2b, a water‐soluble protein (molecular weight = 19,271 Da) produced by recombinant DNA techniques 92. The polymer–drug conjugate is much more effective that the parent interferon alone in the treatment of hepatitis C.…”
Section: Nanomedicine: Dendrimers In Macromolecular Therapeuticsmentioning
confidence: 99%
“…Previously, SPR was used to know the binding partners and its relative interaction strength for IFNs (Takacs et al, 1999;Asokan et al, 2006;Schmeisser et al, 2007), immune response against IFN-β (Gibbs and Oger, 2008) and in one particular instance to quantify IFN-γ (Stigter et al, 2005). However, reports on the use of SPR in the quantification of IFN-α2b are not available in the literature.…”
Section: Introductionmentioning
confidence: 99%
“…PEG has been used extensively because it extends the half-life of most proteins and results in a greatly increased plasma presence (Greenwald, 2001 (Caliceti et al, 1999;Monfardini et al, 1995;Calogerpoulou et al, 2003). The successful application of α-interferon pegylation by ScheringPlough (PEG-INTRON®;molecular weight of PEG 12 kDa daltons;Takacs et al, 1999) and HoffmanLaRoche (Pegasys®;molecular weight of PEG 40 kDa;Bailon PS & Palleroni AV [1997] We (Chong & Chu 2004;Chu et al, 2005) …”
Section: A Nanoparticle Drug-delivery System Is a Device In Which A Dmentioning
confidence: 99%